Automated DNA Extraction System

自动化DNA提取系统

• 批准号: 8052611
• 负责人: THOMAS A SELLERS
• 金额: $ 29.83万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-15 至 2012-05-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052611
• 关键词: Adult Glioma; Aliquot; Applications Grants; Bar Codes; Biological Markers; Boxing; Cancer Center; Caring; Case Series; Contract Services; DNA; DNA Library; Data; Development; Disease; Environmental Risk Factor; Evaluation; Funding; Genetic; Genomics; Genotype; Hereditary Disease; Housing; Human Papillomavirus; Individual; Infection; Liquid substance; Maintenance; Malignant Neoplasms; Malignant neoplasm of prostate; Medicine; Molecular Genetics; Molecular Weight; Mutation; Natural History; Patients; Physiology; Predisposing Factor; Principal Investigator; Process; Protocols documentation; Research Personnel; Research Support; Resource Sharing; Solutions; Somatic Mutation; System; Tissues; Tube; United States National Institutes of Health; Variant; Vendor; base; cancer care; cancer risk; cryogenics; genetic association; genome wide association study; high throughput technology; instrument; instrumentation; men; population based; tumor

DESCRIPTION (provided by applicant): Fundamentally cancer is a genetic disease. Germline variations and somatic mutations influence not only cancer risk but also impact the treatment, progression, and survival of this disease. Thus, to understand the genetic influence of cancer, large-scale genomic based research supported by high-throughput technologies is a necessity. Genomic data opens the "black box" and provides information about the molecular genetic factors that predispose individuals to cancer development, the specific mutations that gave rise to an individual tumor, the physiology of a tumor, and the physiology of the patient. Today a more comprehensive evaluation of germline genetics and tumors profiles is essential for the discovery of biomarkers for individualized medicine and personalized therapy. The purpose of this Shared Instrumentation Grant application is to fund the purchase of a high-throughput DNA extraction system. The requested DNA extraction platform is an integrated solution from two well established vendors in biospecimen automated processing, Qiagen and Tecan. Specifically, the Qiagen AutoPure LS system provides automated purification of archival quality, high molecular weight DNA that is required for DNA banking and population-based genetic association studies. The Qiagen AutoPure system will be integrated with a Tecan EVO 150 liquid handling platform that will enable the assessment of DNA yield, quality, normalization and aliquoting into desired volumes in 2D bar-coded cryogenic tubes. The specific aims for various projects described in this application vary, however they all share the common need for a high-throughput system that can generate high quality DNA to support efforts including genome-wide association studies (GWAS), large case series for studying environmental factors on the onset of adult glioma, prostate cancer biomarker discovery, genotyping and direct sequencing to study the natural history of HPV infection in men. Projected usage of this instrument indicates that it will be well used with the described projects utilizing 74% of capacity. Remaining capacity will be utilized to support other Cancer Center investigators and initiatives such as the Total Cancer Care institutional general banking protocol. The instrument will be housed and operated within the Tissue Core Shared Resource facility. The Cancer Center will provide significant institutional support for this instrumentation by purchasing over $54,000 in yearly service contracts to facilitate the care and maintenance of the both system. Major users described in this proposal are principal investigators on over $24-million dollars in NIH funding.

描述（由申请人提供）：从根本上讲，癌症是一种遗传疾病。种系变异和体细胞突变不仅会影响癌症的风险，而且会影响该疾病的治疗，进展和存活。因此，为了了解癌症的遗传影响，基于高通量技术支持的大规模基因组研究是必要的。基因组数据打开了“黑匣子”，并提供了有关使个体易感癌症发育的分子遗传因素的信息，引起个体肿瘤的特定突变，肿瘤的生理和患者的生理学。如今，对种系遗传学和肿瘤概况的更全面评估对于发现用于个性化医学和个性化疗法的生物标志物至关重要。此共享仪器授予申请的目的是为购买高通量DNA提取系统提供资金。请求的DNA提取平台是来自生物测量自动化处理中两个良好供应商的集成解决方案，即Qiagen和Tecan。具体而言，Qiagen Autopure LS系统提供了档案质量，高分子量DNA的自动纯化，这是DNA库和基于人群的遗传关联研究所必需的。 QIAGEN自动开放系统将与TECAN EVO 150液体处理平台集成，该平台将评估DNA产量，质量，归一化和等分试样中所需的体积。对于本应用程序中描述的各种项目的具体目的各不相同，但是它们都共享了对高通量系统的共同需求，该系统可以产生高质量的DNA，以支持包括全基因组协会研究（GWAS）的努力，大型病例系列，用于研究成人胶质瘤的发作，前列腺癌生物标记，癌症生物标记，基因分型和直接序列序列序列的环境因素，以研究自然史。预计该仪器的用法表明它将与使用74％的容量的所述项目一起很好地使用。剩余的能力将用于支持其他癌症中心研究人员和计划，例如总癌症医疗机构一般银行协议。该仪器将在组织核心共享资源设施中容纳并运行。癌症中心将通过购买超过54,000美元的年度服务合同来促进两种系统的保养和维护，从而为该工具提供大量的机构支持。该提案中描述的主要用户是主要调查人员，其中包括超过2400万美元的NIH资金。